Optimizing Outcomes After Transoral Robotic Surgery for Oropharyngeal Carcinoma: Reflections on the ASCO Guideline [0.03%]
美国临床肿瘤学会指南解读——优化咽癌经口机器人手术治疗效果
Amir H Safavi,Nadeem Riaz,Eric J Sherman et al.
Amir H Safavi et al.
Reply to: Optimizing Outcomes After Transoral Robotic Surgery for Oropharyngeal Carcinoma: Reflections on the ASCO Guideline [0.03%]
关于“优化舌咽癌经口机器人手术后疗效的指南”的评论
F Christopher Holsinger,Nofisat Ismaila,Jamie A Ku
F Christopher Holsinger
Calibrating Chimeric Antigen Receptor (CAR) Signaling to Improve CAR T-Cell Therapies [0.03%]
校准嵌合抗原受体信号转导以改进CAR-T细胞治疗
Cooper J Sailer,Chelsea E Peterson,Marco L Davila
Cooper J Sailer
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study [0.03%]
戈洛菲马结合pola-r-chp或r-chop作为年轻高危大b细胞淋巴瘤患者的一线治疗：COALITION研究结果
Adrian Minson,Emma Verner,Pratyush Giri et al.
Adrian Minson et al.
Purpose: Improved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have 94%. Cytokine release syndrome was observed in 21% of patients, all ≤grade 2 and manageable. Overall and comple...
Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer [0.03%]
新型抗癌疗法或将助力晚期胰腺癌患者治疗取得进展
Michael J Pishvaian
Michael J Pishvaian
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [0.03%]
mismatched无关供者外周血干细胞移植后基于移植后环磷酰胺的移植物抗宿主病预防
Monzr M Al Malki,Stephanie Bo-Subait,Brent Logan et al.
Monzr M Al Malki et al.
Purpose: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with ...
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 [0.03%]
老年晚期经典型霍奇金淋巴瘤患者NRG血液学肿瘤S1826研究：Nivolumab-AVD与Brentuximab Vedotin-AVD的比较
Sarah C Rutherford,Hongli Li,Alex F Herrera et al.
Sarah C Rutherford et al.
Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three S1826 trial conducted by SWOG that rand...
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML [0.03%]
新型低甲基化药物、维奈克拉和异柠檬酸脱氢酶抑制剂三联方案用于不适合接受高强度化疗的异柠檬酸脱氢酶突变急性髓系白血病患者的效果
Courtney D DiNardo,Jennifer Marvin-Peek,Sanam Loghavi et al.
Courtney D DiNardo et al.
Purpose: The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)-ineligible AML: vene...
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study [0.03%]
自体移植治疗晚期皮肤T细胞淋巴瘤患者的总生存期（CUTALLO）：倾向评分匹配的前瞻性队列研究
Adèle de Masson,Marie Beylot-Barry,Caroline Ram-Wolff et al.
Adèle de Masson et al.
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression...
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma [0.03%]
转移性肢端雀斑样黑色素瘤的肿瘤浸润淋巴细胞过继细胞转移治疗
Paul H McClelland,Shirley K Nah,Alexandra M Gustafson et al.
Paul H McClelland et al.
Purpose: Acral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low tumor mutational burden (TMB), and dimini...